Biocon Limited — Board Meeting, 26-06-2025: Outcome of Board Meeting

Biocon has announced a board meeting approving the acquisition of 1,125 Optionally Convertible Debentures (OCDs) of its unlisted subsidiary, Biocon Biologics, from Goldman Sachs’ India Alternative Investment Trust schemes. The face value of each OCD is Rs. 1 Cr, with the total consideration around USD 198.5 million (approx ₹1,650 Cr). This move strengthens Biocon’s hold in its biologics business, signaling confidence in its long-term growth potential. No promoters or related parties are involved in the transaction.